AU693433B2 - Prevention and treatment of sepsis - Google Patents

Prevention and treatment of sepsis Download PDF

Info

Publication number
AU693433B2
AU693433B2 AU62269/94A AU6226994A AU693433B2 AU 693433 B2 AU693433 B2 AU 693433B2 AU 62269/94 A AU62269/94 A AU 62269/94A AU 6226994 A AU6226994 A AU 6226994A AU 693433 B2 AU693433 B2 AU 693433B2
Authority
AU
Australia
Prior art keywords
conjugate
antibiotic
igg
pmb
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU62269/94A
Other languages
English (en)
Other versions
AU6226994A (en
Inventor
Sean B. Carroll
Joseph R Firca
Nisha Vikas Padhye
Charles S. G Pugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Ophidian Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/169,701 external-priority patent/US5545721A/en
Application filed by Ophidian Pharmaceuticals Inc filed Critical Ophidian Pharmaceuticals Inc
Publication of AU6226994A publication Critical patent/AU6226994A/en
Application granted granted Critical
Publication of AU693433B2 publication Critical patent/AU693433B2/en
Assigned to PROMEGA CORPORATION reassignment PROMEGA CORPORATION Alteration of Name(s) in Register under S187 Assignors: OPHIDIAN PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C07K7/58—Bacitracins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
AU62269/94A 1992-12-21 1993-12-20 Prevention and treatment of sepsis Ceased AU693433B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99538892A 1992-12-21 1992-12-21
US995388 1992-12-21
US16406793A 1993-12-08 1993-12-08
US164067 1993-12-08
US169701 1993-12-17
US08/169,701 US5545721A (en) 1992-12-21 1993-12-17 Conjugates for the prevention and treatment of sepsis
PCT/US1993/012381 WO1994014437A1 (fr) 1992-12-21 1993-12-20 Prevention et traitement de la septicemie

Publications (2)

Publication Number Publication Date
AU6226994A AU6226994A (en) 1994-07-19
AU693433B2 true AU693433B2 (en) 1998-07-02

Family

ID=27388964

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62269/94A Ceased AU693433B2 (en) 1992-12-21 1993-12-20 Prevention and treatment of sepsis

Country Status (5)

Country Link
EP (1) EP0679083A4 (fr)
JP (1) JPH08504824A (fr)
AU (1) AU693433B2 (fr)
CA (1) CA2151386A1 (fr)
WO (1) WO1994014437A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO2007038623A2 (fr) * 2005-09-28 2007-04-05 Ventria Bioscience Preparation orale pour troubles enteriques et/ou rehydratation
WO2023080797A1 (fr) * 2021-11-05 2023-05-11 Koru Diagnostics Limited Procédé de détection de micro-organismes pathogènes gram-négatifs et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067776A (en) * 1975-11-25 1978-01-10 Research Foundation Of Children's Hospital Method for differential diagnosis of meningitis with a limulus lysate test
CA1203164A (fr) * 1982-03-09 1986-04-15 Thomas J. Mckearn Conjugats d'anticorps
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
WO1989004672A1 (fr) * 1987-11-20 1989-06-01 The Upjohn Company Derives d'antibiotiques de lincosaminide
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
AU639952B2 (en) * 1989-11-15 1993-08-12 Novartis Ag Polymyxin conjugates
AU2006892A (en) * 1991-05-16 1992-12-30 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
EP0664814A1 (fr) * 1993-08-18 1995-08-02 MorphoSys AG Peptides liant et neturalisant les lipopolysaccharides

Also Published As

Publication number Publication date
AU6226994A (en) 1994-07-19
WO1994014437A1 (fr) 1994-07-07
EP0679083A1 (fr) 1995-11-02
EP0679083A4 (fr) 1999-03-24
CA2151386A1 (fr) 1994-07-07
JPH08504824A (ja) 1996-05-28

Similar Documents

Publication Publication Date Title
US5545721A (en) Conjugates for the prevention and treatment of sepsis
US6579696B1 (en) Polymyxin B conjugates
Gough et al. Antiendotoxin activity of cationic peptide antimicrobial agents
JP4656728B2 (ja) ブドウ球菌抗原及びワクチン
US6660267B1 (en) Prevention and treatment of sepsis
US10870710B2 (en) Synthetic oligosaccharide subunits of the Psl exopolysaccharide of pseudomonas aeruginosa and uses thereof
JPH07501545A (ja) 非連鎖球菌系細菌感染症の治療方法
US5955074A (en) Directed human immune globulin for the prevention and treatment of staphylococcal infections
Bergmann et al. SCM, the M protein of Streptococcus canis binds immunoglobulin G
Poynton et al. Use of IgM enriched intravenous mmmMMlLLL (Pentaglobin) in bone marrow transplantation
Kirikae et al. Biological characterization of endotoxins released from antibiotic-treated Pseudomonas aeruginosa and Escherichia coli
AU693433B2 (en) Prevention and treatment of sepsis
JP3457309B2 (ja) ウイルス感染症の治療方法
Conti et al. In vitro activity of monoclonal and recombinant yeast killer toxin-like antibodies against antibiotic-resistant gram-positive cocci
US5998381A (en) Compounds that bind bacterial pili
WO1993017044A1 (fr) Immunoglobuline humaine dirigee pour la prevention et le traitement de staphylococcies
CN107614517B (zh) 抗感染疾病的抗体
Doran et al. Influence of clindamycin on fibronectin-staphylococcal interactions
KR20110124060A (ko) Ｗｔａ를 유효성분으로 함유하는 백신 조성물
Warren et al. Protective Efficacy of CAP18106–138–Immunoglobulin G in Sepsis
AU6553899A (en) Prevention and treatment of sepsis
JPH05505592A (ja) セプシスの治療用製剤製品
Kim et al. Demonstration of opsonic and protective activity of human cord sera against type III group B streptococcus that are independent of type-specific antibody
Eckhardt et al. Evaluation of protective mAbs against Pseudomonas aeruginosa outer membrane protein I by C1q binding assay
Torney et al. Comparative therapeutic efficacy of teicoplanin and vancomycin in normal and in neutropenic mice infected with Staphylococcus haemolyticus

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: PROMEGA CORPORATION

Free format text: FORMER OWNER WAS: OPHIDIAN PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired